Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-8161 in advanced NRAS-mutant melanoma and other solid tumors
NCT07584226Phase 2Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Mar 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RLY-8161 in melanoma, colorectal cancer (CRC), solid tumor, sponsored by Relay Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
RLY-8161
03
Conditions
melanomacolorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT07584226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584226.